287 related articles for article (PubMed ID: 19528037)
1. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA.
Fritsche P; Seidler B; Schüler S; Schnieke A; Göttlicher M; Schmid RM; Saur D; Schneider G
Gut; 2009 Oct; 58(10):1399-409. PubMed ID: 19528037
[TBL] [Abstract][Full Text] [Related]
2. SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis.
Schüler S; Diersch S; Hamacher R; Schmid RM; Saur D; Schneider G
Int J Oncol; 2011 Jan; 38(1):219-25. PubMed ID: 21109943
[TBL] [Abstract][Full Text] [Related]
3. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.
Ropero S; Fraga MF; Ballestar E; Hamelin R; Yamamoto H; Boix-Chornet M; Caballero R; Alaminos M; Setien F; Paz MF; Herranz M; Palacios J; Arango D; Orntoft TF; Aaltonen LA; Schwartz S; Esteller M
Nat Genet; 2006 May; 38(5):566-9. PubMed ID: 16642021
[TBL] [Abstract][Full Text] [Related]
4. An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1.
Hanigan CL; Van Engeland M; De Bruine AP; Wouters KA; Weijenberg MP; Eshleman JR; Herman JG
Gastroenterology; 2008 Nov; 135(5):1654-1664.e2. PubMed ID: 18834886
[TBL] [Abstract][Full Text] [Related]
5. HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.
Schüler S; Fritsche P; Diersch S; Arlt A; Schmid RM; Saur D; Schneider G
Mol Cancer; 2010 Apr; 9():80. PubMed ID: 20398369
[TBL] [Abstract][Full Text] [Related]
6. HDAC2 deficiency sensitizes colon cancer cells to TNFalpha-induced apoptosis through inhibition of NF-kappaB activity.
Kaler P; Sasazuki T; Shirasawa S; Augenlicht L; Klampfer L
Exp Cell Res; 2008 Apr; 314(7):1507-18. PubMed ID: 18314102
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells.
Sebens Müerköster S; Werbing V; Sipos B; Debus MA; Witt M; Grossmann M; Leisner D; Kötteritzsch J; Kappes H; Klöppel G; Altevogt P; Fölsch UR; Schäfer H
Oncogene; 2007 Apr; 26(19):2759-68. PubMed ID: 17086212
[TBL] [Abstract][Full Text] [Related]
8. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
[TBL] [Abstract][Full Text] [Related]
9. Transforming pathways unleashed by a HDAC2 mutation in human cancer.
Ropero S; Ballestar E; Alaminos M; Arango D; Schwartz S; Esteller M
Oncogene; 2008 Jun; 27(28):4008-12. PubMed ID: 18264134
[TBL] [Abstract][Full Text] [Related]
10. The LIM-only factor LMO4 regulates expression of the BMP7 gene through an HDAC2-dependent mechanism, and controls cell proliferation and apoptosis of mammary epithelial cells.
Wang N; Lin KK; Lu Z; Lam KS; Newton R; Xu X; Yu Z; Gill GN; Andersen B
Oncogene; 2007 Sep; 26(44):6431-41. PubMed ID: 17452977
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
12. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity.
Harms KL; Chen X
Cancer Res; 2007 Apr; 67(7):3145-52. PubMed ID: 17409421
[TBL] [Abstract][Full Text] [Related]
14. Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer.
Arnold NB; Ketterer K; Kleeff J; Friess H; Büchler MW; Korc M
Cancer Res; 2004 May; 64(10):3599-606. PubMed ID: 15150118
[TBL] [Abstract][Full Text] [Related]
15. Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid.
Jones J; Bentas W; Blaheta RA; Makarevic J; Hudak L; Wedel S; Probst M; Jonas D; Juengel E
Int J Mol Med; 2008 Sep; 22(3):293-9. PubMed ID: 18698487
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma.
Angelucci A; Muzi P; Cristiano L; Millimaggi D; Cimini A; Dolo V; Miano R; Vicentini C; Cerù MP; Bologna M
Prostate; 2008 May; 68(6):588-98. PubMed ID: 18288684
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of MIF leads to cell cycle arrest and apoptosis in pancreatic cancer cells.
Denz A; Pilarsky C; Muth D; Rückert F; Saeger HD; Grützmann R
J Surg Res; 2010 May; 160(1):29-34. PubMed ID: 19726058
[TBL] [Abstract][Full Text] [Related]
18. HDAC2 deficiency and histone acetylation.
Ree AH; Folkvord S; Flatmark K
Nat Genet; 2008 Jul; 40(7):812-3; author reply 813. PubMed ID: 18583969
[No Abstract] [Full Text] [Related]
19. Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit.
Takehara A; Hosokawa M; Eguchi H; Ohigashi H; Ishikawa O; Nakamura Y; Nakagawa H
Cancer Res; 2007 Oct; 67(20):9704-12. PubMed ID: 17942900
[TBL] [Abstract][Full Text] [Related]
20. Netrin-1 mediates early events in pancreatic adenocarcinoma progression, acting on tumor and endothelial cells.
Dumartin L; Quemener C; Laklai H; Herbert J; Bicknell R; Bousquet C; Pyronnet S; Castronovo V; Schilling MK; Bikfalvi A; Hagedorn M
Gastroenterology; 2010 Apr; 138(4):1595-606, 1606.e1-8. PubMed ID: 20080097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
